Needle-free Vaccines Lead Intercell to the US with its Latest Acquisition
Sally Mardikian PhD
Abstract
Intercell has turned to the US to acquire Iomai - a company that will expand its travellers vaccine franchise and deliver novel transcutaneous immunization technology.
Full Text: pdf html
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.